Enliven Therapeutics, Inc. (ELVN) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Enliven Therapeutics, Inc.
Address
6200 Lookout Road
Boulder, CO 80301
United States of America (the)
Phone
720 647 8519
Sector
Healthcare
Industry
Biotechnology
Employees
61
First IPO Date
March 12, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Richard A. Fair | CEO, President & Director | 672,656 | 1969 |
| Benjamin Hohl | Chief Financial Officer & Head of Corporate Development | 667,894 | 1989 |
| Joseph Lyssikatos | Co-Founder & Research Fellow | 709,400 | 1965 |
| Helen Louise Collins | Chief Medical Officer | 726,420 | 1963 |
| Samuel S. Kintz | Co-Founder & Head of Pipeline | 956,094 | 1986 |
| Damiette Smit | Vice President of Clinical Development | 0 | N/A |
| Anish Patel | Co-Founder & Chief Operating Officer | 0 | 1981 |
| Galya D. Blachman | Chief Legal Officer & Head of Business Development | 0 | 1977 |
Description
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
